Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; dosimetric findings

被引:0
|
作者
Mok, S. [1 ]
Tay, Y. [1 ]
Ng, D. [1 ]
机构
[1] Singapore Gen Hosp, Singapore, Singapore
关键词
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
P603
引用
收藏
页码:S532 / S532
页数:1
相关论文
共 50 条
  • [31] Disturbing the redox balance as a new radiosensitizing strategy for Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
    Delbart, W.
    Marin, G.
    Stamatopoulos, B.
    Ghanem, G. E.
    Flamen, P.
    Wimana, Z.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S59 - S59
  • [32] Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE
    Zandee, Wouter T.
    Feelders, Richard A.
    Duijzentkunstz, Daan A. Smit
    Hofland, Johannes
    Metselaar, R. Mick
    Oldenburg, Rogier A.
    van Linge, Anne
    Kam, Boen L. R.
    Teunissen, Jaap J. M.
    Korpershoek, Esther
    Hendriks, Johanna M.
    Abusaris, Huda
    Slagter, Cleo
    Franssen, Gaston J. H.
    Brabander, Tessa
    De Herder, Wouter W.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2019, 181 (01) : 45 - 53
  • [33] 177Lu-Dotatate Peptide Receptor Radionuclide Therapy Dose Response in Small Intestinal Neuroendocrine Tumors
    Jahn, U. M. M.
    Ilan, E.
    Sandstrom, M.
    Bamerny, M.
    Garske-Roman, U.
    Lubberink, M.
    Sundin, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S157 - S158
  • [34] Patient-Specific Dosimetry of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy with High Activities
    Beykan, S.
    Eberlein, U.
    Werner, R. A.
    Lapa, C.
    Buck, A. K.
    Kudlich, T.
    Lassmann, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S33 - S33
  • [35] Gallbladder Visualization in Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE A Potential Mimicker of Hepatic Metastases
    Diekmann, Johanna
    Werner, Rudolf A.
    Ross, Tobias L.
    Derlin, Thorsten
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (12) : E521 - E522
  • [36] The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis
    Zhang, Jie
    Song, Qi
    Cai, Liang
    Xie, Ying
    Chen, Yue
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (06) : 1533 - 1543
  • [37] Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
    Levart, D.
    Kalogianni, E.
    Corcoran, B.
    Mulholland, N.
    Vivian, G.
    EJNMMI PHYSICS, 2019, 6 (1)
  • [38] Expanding the Indication for Novel Theranostic 177Lu-Dotatate Peptide Receptor Radionuclide Therapy: Proof-of-Concept of PRRT in Merkel Cell Cancer
    Kasi, Pashtoon M.
    Sharma, Akash
    Jain, Manoj K.
    CASE REPORTS IN ONCOLOGY, 2019, 12 (01): : 98 - 103
  • [39] 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors
    Jahn, Ulrika
    Ilan, Ezgi
    Sandstrom, Mattias
    Garske-Roman, Ulrike
    Lubberink, Mark
    Sundin, Anders
    NEUROENDOCRINOLOGY, 2020, 110 (7-8) : 662 - 670
  • [40] Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the phase I-II Milan protocol
    Bodei, L.
    Cremonesi, M.
    Grana, C. M.
    Baio, S. M.
    Bartolomei, M.
    Ferrari, M.
    Iodice, S.
    Lombardo, D.
    Martano, L.
    Chinol, M.
    Paganelli, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S266 - S267